The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 10, 2025 /EINPresswire / -- How Has the Libtayo Market Evolved, and What Are Its Growth Projections? .Market Growth from 2024 to 2025: oThe Libtayo ...

Arm 1 will administer Libtayo on day 5. The Company plans to ... MAIA expects to conduct the trials in the U.S. and select countries in Europe and Asia. MAIA recently announced an amended clinical ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on the National Health Service. This approval is for second-line monotherapy ...